This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MTSR Metsera (MTSR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Metsera Stock (NASDAQ:MTSR) Get Metsera alerts:Sign Up Key Stats Today's Range$70.13▼$70.7850-Day Range$52.15▼$83.1852-Week Range$12.30▼$83.86Volume27.90 million shsAverage Volume4.84 million shsMarket Capitalization$7.42 billionP/E RatioN/ADividend YieldN/APrice Target$55.75Consensus RatingHold Company Overview Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York. Read More Receive MTSR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Metsera and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MTSR Stock News HeadlinesPfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds ShiftApril 8, 2026 | finance.yahoo.comPfizer Releases Early Obesity Data Showing Up to 12.3% Weight LossFebruary 4, 2026 | finance.yahoo.comYou're not getting into the SpaceX IPO. Do this instead.The SpaceX IPO is expected to price at $1.75 trillion - and retail investors won't get an allocation. Banks and insiders have already locked it up. But there is one small, publicly traded company that builds the critical infrastructure SpaceX cannot operate without. Dylan Jovine is releasing the ticker name today at no cost.May 16 at 1:00 AM | Behind the Markets (Ad)Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth StoryFebruary 4, 2026 | finance.yahoo.comWhy Pfizer's 2026 guidance miss is 'not a major surprise'December 16, 2025 | msn.comMetsera (MTSR): Evaluating Valuation After Sharp Share Price TurnaroundNovember 14, 2025 | finance.yahoo.comMetsera, Inc. Completes Merger and Restructures LeadershipNovember 14, 2025 | msn.comPfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: ReportNovember 13, 2025 | msn.comSee More Headlines MTSR Stock Analysis - Frequently Asked Questions How were Metsera's earnings last quarter? Metsera Inc. (NASDAQ:MTSR) issued its quarterly earnings results on Monday, July, 28th. The company reported ($0.66) earnings per share (EPS) for the quarter. When did Metsera IPO? Metsera (MTSR) raised $244 million in an initial public offering on Friday, January 31st 2025. The company issued 15,277,778 shares at a price of $15.00-$17.00 per share. Company Calendar Last Earnings7/28/2025Today5/16/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MTSR Previous SymbolNASDAQ:MTSR CIK2040807 WebN/A Phone(212) 784-6595FaxN/AEmployees81Year Founded2022Price Target and Rating Average Price Target for Metsera$55.75 High Price Target$62.00 Low Price Target$50.00 Potential Upside/Downside-20.9%Consensus RatingHold Rating Score (0-4)2.33 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($6.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$209.13 million Net MarginsN/A Pretax MarginN/A Return on Equity-121.12% Return on Assets-53.54% Debt Debt-to-Equity RatioN/A Current Ratio4.25 Quick Ratio5.26 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.20 per share Price / Book22.03Miscellaneous Outstanding Shares105,293,000Free FloatN/AMarket Cap$7.42 billion OptionableN/A BetaN/A Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:MTSR) was last updated on 5/16/2026 by MarketBeat.com Staff. From Our PartnersTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredOil is settling in yuan now - here's what that means for goldSaudi Arabia has terminated its 1974 petrodollar agreement with the United States - the deal that forced every...Golden Portfolio | SponsoredThe cat is out the bagAlmost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered s...Porter & Company | SponsoredCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSpaceX is chump change compared to Elon’s $20T ‘iPhone’Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...StocksToTrade | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metsera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metsera With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
